Charles Dharmani

Charles Dharmani

Auto-generated profile, based on publicly available information

Charles Dharmani

Daiichi Sankyo, Inc

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2022 in Future Oncology
Verified
Journal Article
Open access
CDCharles Dharmani
Charles Dharmani
EWEric Wang
Eric Wang
MSMaribel Salas
Maribel Salas
CMColleen McCabe
Colleen McCabe
ADAlvileen Diggs
Alvileen Diggs
VKVicki L Keedy
Vicki L Keedy
For drugs with enhanced serious safety risks, Risk Evaluation and Mitigation Strategy (REMS) may be required. Pexidartinib is approved for treatment of adult symptomatic tenosynovial giant cell tum... Plain language summary For drugs with serious side effects, specific safety measures may be put in place to manage these serious side effects in the form of Risk Evaluation and Mitigation Strategy ...

12 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
BBBlanca Boluda
Blanca Boluda
ASAntonio Solana-Altabella
Antonio Solana-Altabella
ICIsabel Cano
Isabel Cano
DMDavid Martínez-Cuadrón
David Martínez-Cuadrón
EAEvelyn Acuña-Cruz
Evelyn Acuña-Cruz
PMPau Montesinos
Pau Montesinos
The incidence of cardiac morbimortality in acute myeloid leukemia (AML) is not well known. We aim to estimate the cumulative incidence (CI) of cardiac events in AML patients and to identify risk factors for their occurrence. Among 571 newly diagnosed AML patients, 26 (4.6%) developed fatal cardiac events, and among 525 treated patients, 19 (3.6%) experienced fatal cardiac events (CI: 2% at 6 months; 6.7% at 9 years). Prior heart disease was associated with the development of fatal cardiac events (hazard ratio (HR) = 6.9). The CI of non-fatal cardiac events was 43.7% at 6 months and 56.9% at 9 years. Age ≥ 65 (HR = 2.2), relevant cardiac antecedents (HR = 1.4), and non-intensive chemotherapy (HR = 1.8) were associated with non-fatal cardiac events. The 9-year CI of grade 1–2 QTcF prolongation was 11.2%, grade 3 was 2.7%, and no patient had grade 4–5 events. The 9-year CI of grade 1–2 cardiac failure was 1.3%, grade 3–4 was 15%, and grade 5 was 2.1%; of grade 1–2, arrhythmia was 1.9%, grade 3–4 was 9.1%, and grade 5 was 1%. Among 285 intensive therapy patients, median overall survival decreased in those experiencing grade 3–4 cardiac events (p < 0.001). We observed a high incidence of cardiac toxicity associated with significant mortality in AML.

1 January 2023 in Future Oncology
Verified
Journal Article
Open access
CDCharles Dharmani
Charles Dharmani
EWEric Wang
Eric Wang
NTNora Tu
Nora Tu
MSMaribel Salas
Maribel Salas
YKYasser Mostafa Kamel
Yasser Mostafa Kamel
Background: Without treatment, acute myeloid leukemia (AML) is rapidly fatal. Nevertheless, a large proportion of elderly AML patients do not receive any treatment. Aim: To characterize the demogra... Plain language summary An analysis of the data collected in the Surveillance, Epidemiology and End Results-Medicare database from 2008 to 2015 was performed. This database includes data collected b...

18 July 2024 in Future Oncology
Verified
Journal Article
Open access
CDCharles Dharmani
Charles Dharmani
OFOluwatosin Fofah
Oluwatosin Fofah
MFMaura Fallon
Maura Fallon
ARAbdul Waheed Rajper
Abdul Waheed Rajper
MWMargaret Wooddell
Margaret Wooddell
MSMaribel Salas
Maribel Salas
Aim: Hepatic safety data assessment from the TURALIO® (pexidartinib) Risk Evaluation and Mitigation Strategy (tREMS) Program.Methods: Retrospective 3-year assessment (August 2019 to June 2022) of hepatic events from the TURALIO® (pexidartinib) Risk Evaluation and Mitigation Strategy Program.Results: A total of 451 patients, 369 prescribers, 2 wholesalers/distributors and 2 pharmacies were enrolled and certified. Twenty-one (4.7%) patients met the criteria for a hepatic adverse event or laboratory abnormality suggestive of serious and potentially fatal liver injury, all with onset within 2 months of therapy. No new hepatic safety signals were identified.Conclusion: Results are consistent with the phase 3 ENLIVEN trial data. Liver enzyme monitoring, combined with early intervention, including dose modification and discontinuation, conducted in patients treated with pexidartinib mitigate the risk of potential hepatotoxicity.

15 March 2024 in Biomarkers in Medicine
Verified
Journal Article
Closed access
EWEric Wang
Eric Wang
MHMackenzie Henderson
Mackenzie Henderson
PYPriyanka Yalamanchili
Priyanka Yalamanchili
JCJenilee Cueto
Jenilee Cueto
ZIZahidul Islam
Zahidul Islam
MSMaribel Salas
Maribel Salas
Breast cancer treatments have evolved rapidly, and clinically meaningful biomarkers have been used to guide therapy. These biomarkers hold utility within the drug development process to increase th...

21 February 2024 in Future Oncology
Verified
Journal Article
Open access
CDCharles Dharmani
Charles Dharmani
OFOluwatosin Fofah
Oluwatosin Fofah
EWEric Wang
Eric Wang
MSMaribel Salas
Maribel Salas
MWMargaret Wooddell
Margaret Wooddell
GTGabriel Tinoco
Gabriel Tinoco
Aim: Real-world treatment patterns in tenosynovial giant cell tumor (TGCT) patients remain unknown. Pexidartinib is the only US FDA-approved treatment for TGCT associated with severe morbidity or f... Plain language summary – Treatment patterns in patients with tenosynovial giant cell tumors in the USA This database study is the first investigation of how drugs are used to treat patients with te...